OOIR: Observatory of International Research

Papers

(The H4-Index of Clinical and Experimental Allergy is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID‐19 vaccine	173
Incidence and risk factors for persistent symptoms in adults previously hospitalized for COVID‐19	102
Effectiveness and safety of dupilumab for the treatment of severe asthma in a real‐life French multi‐centre adult cohort	77
Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases	72
Expression of ACE2 in airways: Implication for COVID‐19 risk and disease management in patients with chronic inflammatory respiratory diseases	61
Clinical manifestations and impact on daily life of allergy to polyethylene glycol (PEG) in ten patients	54
Real‐world experience with mepolizumab: Does it deliver what it has promised?	53
Real‐life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype	51
Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double‐blind placebo‐controlled trial	48
Omalizumab in the treatment of adult patients with mastocytosis: A systematic review	47
The use of biologics in food allergy	46
The epidemiology of eczema in children and adults in England: A population‐based study using primary care data	44
Interleukin‐17 is a potential player and treatment target in severe chronic spontaneous urticaria	42
Mechanisms of oral immunotherapy	38
Paediatric and adolescent asthma: A narrative review of telemedicine and emerging technologies for the post‐COVID‐19 era	37
Staphylococcus aureus enterotoxin B disrupts nasal epithelial barrier integrity	36
Skincare interventions in infants for preventing eczema and food allergy: A cochrane systematic review and individual participant data meta‐analysis	35
The association between COVID‐19 and asthma: A systematic review and meta‐analysis	32
Real‐world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta‐analysis	32
Antihistamine‐resistant chronic spontaneous urticaria remains undertreated: 2‐year data from the AWARE study	31
BSACI 2021 guideline for the management of egg allergy	31
Digital health interventions in children with asthma	30
The airway fungal microbiome in asthma	30
APPEAL‐2: A pan‐European qualitative study to explore the burden of peanut‐allergic children, teenagers and their caregivers	29
A randomized, placebo‐controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER)	29

Adverse reactions to COVID‐19 vaccines: A practical approach	27
Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate‐to‐severe asthma	27
Frequency of guideline‐defined cow's milk allergy symptoms in infants: Secondary analysis of EAT trial data	27
Clinical evaluation of type 2 disease status in a real‐world population of difficult to manage asthma using historic electronic healthcare records of blood eosinophil counts	27
Treatment effectiveness for Vocal Cord Dysfunction in adults and adolescents: A systematic review	27
Treating severe asthma: Targeting the IL‐5 pathway	27